Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Common Equity (2020 - 2025)

Treace Medical Concepts' Common Equity history spans 6 years, with the latest figure at $87.3 million for Q4 2025.

  • For Q4 2025, Common Equity fell 22.64% year-over-year to $87.3 million; the TTM value through Dec 2025 reached $87.3 million, down 22.64%, while the annual FY2025 figure was $87.3 million, 22.64% down from the prior year.
  • Common Equity reached $87.3 million in Q4 2025 per TMCI's latest filing, down from $89.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $157.6 million in Q1 2023 to a low of -$684000.0 in Q1 2021.
  • Average Common Equity over 5 years is $99.7 million, with a median of $100.3 million recorded in 2021.
  • The largest YoY upside for Common Equity was 130167.09% in 2021 against a maximum downside of 137.92% in 2021.
  • A 5-year view of Common Equity shows it stood at $93.1 million in 2021, then tumbled by 34.97% to $60.5 million in 2022, then skyrocketed by 127.89% to $137.9 million in 2023, then decreased by 18.16% to $112.9 million in 2024, then decreased by 22.64% to $87.3 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Common Equity are $87.3 million (Q4 2025), $89.2 million (Q3 2025), and $97.6 million (Q2 2025).